Literature DB >> 17096327

RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.

Naohito Sato1, Takayuki Fukui, Tetsuo Taniguchi, Toshihiko Yokoyama, Masashi Kondo, Tetsuro Nagasaka, Yasuhiro Goto, Wentao Gao, Yuichi Ueda, Kohei Yokoi, John D Minna, Hirotaka Osada, Yutaka Kondo, Yoshitaka Sekido.   

Abstract

Identification of a homozygous deletion in cancer cells provides strong evidence for the location of a tumor suppressor gene (TSG). We analyzed the 2p24 homozygous deletion of a non-small-cell lung cancer (NSCLC) cell line, NCI-H2882, and found that the deletion size was 3.7 Mbp. Since RhoB, which has been suggested to be a candidate TSG, was located in this region, we analyzed RhoB for alterations in NSCLC. Although we found no mutations in 48 cell lines including 20 NSCLCs, a loss of heterozygosity (LOH) analysis in 128 primary NSCLCs showed that 25 of 62 informative samples had LOH at the RhoB locus. Northern blot analysis of 28 cell lines (including 15 NSCLCs) indicated that RhoB expression was downregulated in 27. We analyzed RhoB expression in 112 primary NSCLCs with immunohistochemistry and found no or a weak RhoB expression in 33 (42%) of 78 adenocarcinomas, whereas we found it in 29 (94%) of 31 squamous cell carcinomas. No or a weak expression of RhoB was more frequently observed in poorly- or moderately-differentiated adenocarcinomas than in well-differentiated ones (p = 0.0014). Furthermore, no or a weak expression of RhoB indicated a tendency to poor patient prognosis. Although hypermethylation was not found at the promoter region, the RhoB expression in NSCLC cell lines was induced by histone deacetylase inhibition, suggesting that RhoB downregulation may be due to histone modification. The present study demonstrates that RhoB expression is frequently downregulated in NSCLCs by multiple mechanisms, suggesting that RhoB is a candidate TSG for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17096327     DOI: 10.1002/ijc.22328

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Authors:  Diego Luis-Ravelo; Iker Antón; Carolina Zandueta; Karmele Valencia; María-José Pajares; Jackeline Agorreta; Luis Montuenga; Silvestre Vicent; Ignacio I Wistuba; Javier De Las Rivas; Fernando Lecanda
Journal:  Mol Oncol       Date:  2013-11-12       Impact factor: 6.603

Review 2.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

3.  RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.

Authors:  E Bousquet; O Calvayrac; J Mazières; I Lajoie-Mazenc; N Boubekeur; G Favre; A Pradines
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

4.  Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.

Authors:  Mark E Hatley; David M Patrick; Matthew R Garcia; James A Richardson; Rhonda Bassel-Duby; Eva van Rooij; Eric N Olson
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

5.  Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.

Authors:  Chunyu Zhang; Abdel G Elkahloun; Hongling Liao; Shannon Delaney; Barbara Saber; Betsy Morrow; George C Prendergast; M Christine Hollander; Joell J Gills; Phillip A Dennis
Journal:  Mol Cancer Ther       Date:  2011-05-06       Impact factor: 6.261

Review 6.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

Review 7.  RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.

Authors:  Olivier Calvayrac; Anne Pradines; Gilles Favre
Journal:  Small GTPases       Date:  2016-11-01

8.  Critical functions of RhoB in support of glioblastoma tumorigenesis.

Authors:  Yufang Ma; Yuanying Gong; Zhixiang Cheng; Sudan Loganathan; Crystal Kao; Jann N Sarkaria; Ty W Abel; Jialiang Wang
Journal:  Neuro Oncol       Date:  2014-09-12       Impact factor: 12.300

9.  RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.

Authors:  Shiva Kazerounian; Damien Gerald; Minzhou Huang; Y Rebecca Chin; Durga Udayakumar; Ningning Zheng; Rebekah K O'Donnell; Carole Perruzzi; Lee Mangiante; Jacob Pourat; Thuy L Phung; Arturo Bravo-Nuevo; Sharon Shechter; Stephanie McNamara; James B Duhadaway; Olivier N Kocher; Lawrence F Brown; Alex Toker; George C Prendergast; Laura E Benjamin
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

10.  Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice.

Authors:  Aaron D DeWard; Kellie Leali; Richard A West; George C Prendergast; Arthur S Alberts
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.